Practically scheduling hormone therapy for prostate cancer using a mathematical model
From MaRDI portal
Publication:2317045
Recommendations
- Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer
- Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer
- A mathematical model of intermittent androgen suppression for prostate cancer
- Nonlinear system identification for prostate cancer and optimality of intermittent androgen suppression therapy
- Mathematical modelling of prostate cancer growth and its application to hormone therapy
Cites work
- A mathematical model of intermittent androgen suppression for prostate cancer
- A mathematical model of prostate tumor growth and androgen-independent relapse
- A mathematical model of prostate tumor growth under hormone therapy with mutation inhibitor
- A model at the macroscopic scale of prostate tumor growth under intermittent androgen suppression
- A new protocol for intermittent androgen suppression therapy of prostate cancer with unstable saddle-point dynamics
- A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer
- Analysis of tracer particle migration in inhomogeneous turbulence
- Bootstrap methods: another look at the jackknife
- Cancer immunotherapy, mathematical modeling and optimal control
- Cell resensitization after delivery of a cycle-specific anticancer drug and effect of dose splitting: learning from tumour cords
- Comparison between mathematical models of intermittent androgen suppression for prostate cancer
- Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer
- Dynamical aspects of a hybrid system describing intermittent androgen suppression therapy of prostate cancer
- Evolution of resistance to anti-cancer therapy during general dosing schedules
- scientific article; zbMATH DE number 3080061 (Why is no real title available?)
- Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer
- MATHEMATICAL MODELING OF PROSTATE TUMOR GROWTH UNDER INTERMITTENT ANDROGEN SUPPRESSION WITH PARTIAL DIFFERENTIAL EQUATIONS
- Mathematically modeling the biological properties of gliomas: A review
- Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers
- Model predictive control. With a foreword by M. J. Grimble and M. A. Johnson
- Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth
- Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer
- Optimization of interleukin-21 immunotherapeutic strategies
- Parameter estimation and optimal scheduling algorithm for a mathematical model of intermittent androgen suppression therapy for prostate cancer
- Permutation complexity in dynamical systems. Ordinal patterns, permutation entropy and all that
- Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer
- Stability analysis on a hybrid PDE-ODE system describing intermittent hormonal therapy of prostate cancer
- Switching in systems and control
- Tissue transport affects how treatment scheduling increases the efficacy of chemotherapeutic drugs
- Using adaptive model predictive control to customize maintenance therapy chemotherapeutic dosing for childhood acute lymphoblastic leukemia
Cited in
(5)- Modeling the synergistic properties of drugs in hormonal treatment for prostate cancer
- Parameter estimation and optimal scheduling algorithm for a mathematical model of intermittent androgen suppression therapy for prostate cancer
- Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer
- Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer
- Mathematical modelling of prostate cancer growth and its application to hormone therapy
This page was built for publication: Practically scheduling hormone therapy for prostate cancer using a mathematical model
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2317045)
